Expert Answers to Common Questions About MET Exon 14Skipping Mutations in NSCLC
b'Host: Mark Socinski, MD
\\n\\n Guest: Patrick Forde, M.B.B.Ch.
\\n\\n Guest: Karen Reckamp, MS, MD
\\n\\n\\n \\n
Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-generation sequencing (NGS) has expanded the understanding of actionable molecular alterations, and in tandem has accelerated the development of drugs to inhibit alterations with greater specificity, leading to the development of novel target-selected agents in NSCLC.
The NCCN Guidelines strongly advise assessment of at least 8 targets for NSCLC by NGS, including MET exon 14\\u2013skipping mutations (METex14). The FDA has approved two MET inhibitors, capmatinib and tepotinib, for patients with METex14 metastatic NSCLC, and there is ongoing research for other targeted agents. Studies have established that treatment with MET-targeted therapies improves outcomes in patients with METex14, as opposed to patients receiving chemotherapy and/or immunotherapy, which generate a modest activity response.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. That\\u2019s why this activity will \\u2026'